Drug Profile
Breast cancer vaccine - Quantum Immunologics
Alternative Names: OFA/iLRP-loaded autologous monocyte-derived dendritic cellsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of South Alabama
- Developer Quantum Immunologics; University of South Alabama
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 24 Sep 2015 No development reported - Phase-I/II for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
- 01 May 2008 Phase-I/II clinical trials in Breast cancer in USA (Intradermal)